1. Home
  2. EYPT vs ATEN Comparison

EYPT vs ATEN Comparison

Compare EYPT & ATEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EYPT

EyePoint Pharmaceuticals Inc.

HOLD

Current Price

$13.36

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

Logo A10 Networks Inc.

ATEN

A10 Networks Inc.

HOLD

Current Price

$26.88

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
EYPT
ATEN
Founded
1987
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
EDP Services
Sector
Industrials
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
2005
2014

Fundamental Metrics

Financial Performance
Metric
EYPT
ATEN
Price
$13.36
$26.88
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
6
Target Price
$31.80
$26.33
AVG Volume (30 Days)
786.6K
1.0M
Earning Date
05-06-2026
04-28-2026
Dividend Yield
N/A
0.90%
EPS Growth
N/A
N/A
EPS
N/A
0.57
Revenue
$7,539,000.00
$235,429,000.00
Revenue This Year
N/A
$13.02
Revenue Next Year
$3,115.57
$10.82
P/E Ratio
N/A
$46.91
Revenue Growth
N/A
2.36
52 Week Low
$5.46
$16.18
52 Week High
$19.11
$28.59

Technical Indicators

Market Signals
Indicator
EYPT
ATEN
Relative Strength Index (RSI) 43.22 60.18
Support Level $12.47 $17.08
Resistance Level $13.32 $28.59
Average True Range (ATR) 0.63 1.04
MACD -0.11 -0.16
Stochastic Oscillator 27.50 53.01

Price Performance

Historical Comparison
EYPT
ATEN

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

About ATEN A10 Networks Inc.

A10 Networks Inc is a provider of security and infrastructure solutions for on-premises, hybrid cloud, and edge-cloud environments of its multinational enterprise, communication, cloud and web service provider customers who strive to provide business-critical applications and networks that are secure, available, and efficient. As cyber-attacks increase in volume and complexity, the company integrates security and artificial intelligence (AI) enabled capabilities in its solutions that enable its customers to continue to adapt to market trends in hybrid cloud, AI-ready data centers and the ever-increasing need for high-performance, high availability and low latency. The company generates the maximum of its revenue from Americas.

Share on Social Networks: